AR and prostate carcinoma: Given that IL-6 is an autocrine and paracrine growth factor involved in CRPC development, prostate cancer metastasis and chemo-resistance of prostate cancer [28,30,31,32,33], our results suggest that the effects of AR-V7 on CRPC development and prostate cancer progression may be mediated in part via activation of NF-κB/IL-6 signaling in the tumor cells.